Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

505.43 +8.31 (+1.67%)
Streaming Delayed Price Updated: 10:28 AM EDT, Sep 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about United Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
1 Cash-Heavy Stock to Target This Week and 2 We Question
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion o... 
Via StockStory
News headline image
Therapeutics Stocks Q2 Teardown: United Therapeutics (NASDAQ:UTHR) Vs The Rest
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including United Therapeutics (NASDAQ:UTHR) and its peers. Ove... 
Via StockStory
Topics Artificial Intelligence
United Therapeutics (NASDAQ:UTHR) Fits the Growth-at-a-Reasonable-Price Model ↗
Via Chartmill
News headline image
3 Profitable Stocks We’re Skeptical Of
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does... 
Via StockStory
News headline image
3 Cash-Producing Stocks We Keep Off Our Radar
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff... 
Via StockStory
United Therapeutics (NASDAQ:UTHR) Stands Out as a Quality Stock with Durable Profitability and Strong Returns ↗
Via Chartmill
United Therapeutics (NASDAQ:UTHR): A Peter Lynch-Style GARP Play ↗
Via Chartmill
United Therapeutics (NASDAQ:UTHR) Tumbles as Q2 Revenue Misses Despite EPS Beat ↗
Via Chartmill
United Therapeutics (NASDAQ:UTHR) Shares Dip After Q1 2026 Earnings Miss ↗
Via Chartmill
News headline image
United Therapeutics (UTHR) Q2 2026 Earnings Call Transcript ↗
CEO Rothblatt calls H1 2026 "one of the most consequential periods" in company history. 
Via The Motley Fool
Topics Earnings
News headline image
United Therapeutics’s Q2 Earnings Call: Our Top 5 Analyst Questions
United Therapeutics reported second quarter results that modestly exceeded Wall Street’s revenue and adjusted EPS expectations, with management highlighting ... 
Via StockStory
Topics Earnings
News headline image
UTHR Q2 2026 Deep Dive: Product Pipeline Developments Offset Competitive Pressures
Biotechnology company United Therapeutics (NASDAQ:UTHR) beat Wall Street’s revenue expectations in Q2 CY2026, but sales fell by 1.9% year on year to $783.3 m... 
Via StockStory
News headline image
United Therapeutics Q2 Earnings Call Highlights ↗
United Therapeutics (NASDAQ:UTHR) reported second-quarter 2026 revenue of approximately $783 million, essentially flat from the first quarter, as competitive pressure affected sales of its nebulized... 
Via MarketBeat
Topics Earnings
News headline image
United Therapeutics (NASDAQ:UTHR) Surprises With Q2 CY2026 Sales
Biotechnology company United Therapeutics (NASDAQ:UTHR) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, but sales fell by 1.9% year on yea... 
Via StockStory
Topics Artificial Intelligence
News headline image
Earnings To Watch: United Therapeutics (UTHR) Reports Q2 Results Tomorrow
Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting results this Wednesday before the bell. Here’s what you need to know. United Therap... 
Via StockStory
News headline image
United Therapeutics CEO Sells $5 Million of Shares. What Does This Mean for Investors? ↗
Martine Rothblatt exercised options at $135.42 and sold at $530.42 under a pre-established Rule 10b5-1 plan, reducing her stake by just 1% while maintaining $353.1 million in equity value. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Therapeutics Stocks Q1 Recap: Benchmarking Biogen (NASDAQ:BIIB)
Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q1 therapeutics earnings season. Over the next ... 
Via StockStory
Topics Artificial Intelligence
News headline image
Q1 Earnings Outperformers: United Therapeutics (NASDAQ:UTHR) And The Rest Of The Therapeutics Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking a... 
Via StockStory
Topics Artificial Intelligence
News headline image
These 3 Stocks Lowered Their Share Counts Drastically in Q1 ↗
Pinterest, Southwest Airlines, and United Therapeutics each executed significant share repurchases in Q1 2026, reducing their outstanding share counts by 16%, 5%, and 3.2%, respectively. 
Via MarketBeat
News headline image
1 Cash-Producing Stock with Exciting Potential and 2 We Ignore
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff... 
Via StockStory
Topics Energy
News headline image
What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year ↗
Ultragenyx develops therapies for rare genetic diseases, with a portfolio spanning approved biologics and a pipeline of gene therapies. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
2 Mid-Cap Stocks on Our Buy List and 1 We Turn Down
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe... 
Via StockStory
Topics Credit Cards
News headline image
5 Insightful Analyst Questions From United Therapeutics’s Q1 Earnings Call
United Therapeutics' first quarter results fell below Wall Street's revenue and earnings expectations, but the market responded favorably. Management attribu... 
Via StockStory
Topics Earnings
News headline image
UTHR Q1 Deep Dive: Pipeline Advances and Product Launches Dominate Outlook
Biotechnology company United Therapeutics (NASDAQ:UTHR) fell short of the market’s revenue expectations in Q1 CY2026, with sales falling 1.6% year on year to... 
Via StockStory
News headline image
UTHR Q1 2026 Earnings Transcript ↗
UTHR Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
United Therapeutics (NASDAQ:UTHR) Reports Sales Below Analyst Estimates In Q1 CY2026 Earnings
Biotechnology company United Therapeutics (NASDAQ:UTHR) missed Wall Street’s revenue expectations in Q1 CY2026, with sales falling 1.6% year on year to $781.... 
Via StockStory
Topics Artificial Intelligence
News headline image
United Therapeutics (UTHR) Q1 Earnings Report Preview: What To Look For
Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting results this Wednesday before market hours. Here’s what to look for. United Therape... 
Via StockStory
Topics Artificial Intelligence
News headline image
The eVTOL Era is Beginning With Uber and Joby Aviation: What Investors Need to Know ↗
The eVTOL market is preparing for takeoff in 2026, but which stocks will win out over the long term? 
Via The Motley Fool
News headline image
UTHR Q4 2025 Earnings Transcript ↗
UTHR Q4 2025 Earnings Transcript 
Via The Motley Fool
News headline image
3 Reasons Investors Love United Therapeutics (UTHR)
Since April 2021, the S&P 500 has delivered a total return of 68.6%. But one standout stock has more than doubled the market - over the past five years, Unit... 
Via StockStory
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.